The US Food and Drug Administration (FDA) has approved a number of new drugs in 2023, including treatments for cancer, Alzheimer’s disease, and other serious conditions. Here are some of the most notable new drugs released in the market.
Leqembi (lecanemab)
Leqembi is a new drug for the treatment of early Alzheimer’s disease. It is a monoclonal antibody that targets amyloid beta, a protein that is thought to play a role in the development of Alzheimer’s disease. Leqembi is the first drug to show a statistically significant slowing of cognitive decline in patients with early Alzheimer’s disease.
Agamree (vamorolone)
Agamree is a new drug for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare genetic disease that causes muscle weakness and degeneration. Agamree is a corticosteroid that is designed to have fewer side effects than traditional corticosteroids. In clinical trials, Agamree was shown to improve muscle function and slow disease progression in patients with DMD.
Rivfloza (nedosiran)
Rivfloza is a new drug for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a rare genetic disease that causes the body to produce too much oxalate, a chemical that can form stones in the kidneys and other organs. Rivfloza is a small interfering RNA (siRNA) that blocks the production of oxalate. In clinical trials, Rivfloza was shown to reduce oxalate levels and improve kidney function in patients with PH1.
Xpovio (selpercatinib)
Xpovio is a new drug for the treatment of non-small cell lung cancer (NSCLC) with RET fusions. RET fusions are genetic alterations that can lead to the uncontrolled growth of cancer cells. Xpovio is a tyrosine kinase inhibitor (TKI) that targets RET fusions. In clinical trials, Xpovio was shown to shrink tumors and improve survival in patients with NSCLC with RET fusions.
Reblozyl (luspatercept)
Reblozyl is a new drug for the treatment of beta thalassemia and sickle cell disease. These are rare genetic blood disorders that can cause anemia. Reblozyl is a fusion protein that activates erythropoietin receptors, which are receptors that stimulate the production of red blood cells. In clinical trials, Reblozyl was shown to reduce the need for blood transfusions and improve quality of life in patients with beta thalassemia and sickle cell disease.
These are just a few of the new drugs that have been approved by the FDA in 2023.
Read also: The Biggest Biopharma Companies in 2023.
